Company Filing History:
Years Active: 2025
Title: Hayato Shiotsu: Innovator in KRAS G12D Modulating Compounds
Introduction
Hayato Shiotsu is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that target specific mutations in the KRAS gene.
Latest Patents
Hayato Shiotsu holds a patent for KRAS G12D modulating compounds. This patent includes compounds and pharmaceutically acceptable salts that are useful as KRAS G12D and/or KRAS G12C inhibitors. The patent outlines methods of making and using these compounds, either alone or in combination with additional agents, as well as the pharmaceutical compositions derived from them. He has 1 patent to his name.
Career Highlights
Hayato Shiotsu is currently employed at Gilead Sciences, Inc., a leading biopharmaceutical company. His work focuses on innovative solutions for treating diseases associated with genetic mutations, showcasing his commitment to advancing medical science.
Collaborations
Hayato collaborates with Chaodi Dai, a fellow researcher, to further explore the potential of KRAS inhibitors in therapeutic applications.
Conclusion
Hayato Shiotsu's work in developing KRAS G12D modulating compounds represents a significant advancement in targeted therapies. His contributions to the field continue to pave the way for innovative treatments in oncology.